Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
about
Mobilization, Isolation and Characterization of Stem Cells from Peripheral Blood: a Systematic ReviewSupportive care in patients with acute leukaemia: historical perspectives.Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a GruppThe prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies.The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter I: current practice and remaining unmet medical needs.Hematopoietic stem cell mobilization: current status and future perspective.Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients.Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.How do we mobilize and collect autologous peripheral blood stem cells?Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations.Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.Stem Cell Mobilization with G-CSF versus Cyclophosphamide plus G-CSF in Mexican Children.Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly.Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma.Decision-tree algorithm for optimized hematopoietic progenitor cell-based predictions in peripheral blood stem cell mobilization.Cost analysis of a randomized stem cell mobilization study in multiple myeloma.UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score.Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.Plerixafor: what we still have to learn.Recombinant human thrombopoietin improves the efficacy of intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor in mobilizing peripheral blood stem cells in patients with multiple myeloma: A cohort study.Impact of plerixafor (mozobil) on hospital efficiency: A single center experience.Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the "on-demand" scheme of administration at French autologous hematopoietic stem cell transplant programs.Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers.Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.
P2860
Q33652381-31920BAA-D97A-43AD-9558-F2B348A60BBFQ35265135-F2C5D810-8A0C-4100-A4E2-2A5F0213625DQ35588325-715AC62E-FAE2-4E1B-BCBB-8C3B22B4A5A6Q38256923-A64CEFBE-1CEE-47D4-B276-321C90DA3E13Q38453666-3FEEEF42-22D3-4EB5-8800-4C3B6E705A51Q38658893-EC6208E5-68C6-4281-B175-ABE04563A81AQ38808625-9B151B5D-FDB1-4230-858D-E12C74D784ABQ38880504-BCB8D38E-C009-449F-94CC-A811205CCBBAQ38978669-0097D475-5846-45C8-8242-7D09ABE67DF4Q40407349-173CF9F6-1FFB-4AD9-86F2-D8BE977B392BQ41003137-7DC6D70A-E675-464F-8AC9-B37D32D09C57Q41855505-975F3A04-039C-4403-842B-BFD6EDA30207Q42380588-501865EE-FF75-44C2-B343-F486A5AF303DQ47696715-75C2922F-2327-4CD9-8FCF-075451797CA1Q47914097-7EF6078E-6D5C-4D7F-8BD1-9D593FE79164Q48054177-46376315-F3EF-4657-96C6-B4283B405FE8Q48130246-821DE558-5372-4C14-8228-B9C65C342A5DQ48251584-94CC67D2-CFC2-48E4-AFF9-EF9CDA56A87DQ48251589-1CBBF61D-649F-461F-8F8A-5737C192D3CAQ48337454-F61A0E62-A3B2-4393-A372-8F0BAA32F765Q48747463-443179BC-8575-4ADE-A861-0301F8B8501FQ49487144-16E8C259-89DE-4218-A125-2E03225343FDQ50690379-45B3E662-DFCD-4108-8461-A37CC19F3798Q51004201-FFCC89AD-DA64-4F3C-A144-9C69B48EE104Q53508311-43FF2647-5025-4386-8E88-2B12B41509F4Q54582789-AF056164-9F88-43C6-A4A5-C73B1C3300E3Q55094338-B8E19D28-6CBB-446E-A63B-B24A35EDAC4F
P2860
Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Plerixafor on-demand combined ...... est with no increase in costs.
@en
Plerixafor on-demand combined ...... est with no increase in costs.
@nl
type
label
Plerixafor on-demand combined ...... est with no increase in costs.
@en
Plerixafor on-demand combined ...... est with no increase in costs.
@nl
prefLabel
Plerixafor on-demand combined ...... est with no increase in costs.
@en
Plerixafor on-demand combined ...... est with no increase in costs.
@nl
P2093
P2860
P356
P1476
Plerixafor on-demand combined ...... est with no increase in costs.
@en
P2093
Alessandra Cupri
Andrea Spadaro
Annalia Di Marco
Elena Schinocca
Eleonora Spina
Giovanni Tripepi
Potito Scalzulli
Salvatore Leotta
Valentina Di Martina
P2860
P304
P356
10.1111/BJH.12606
P407
P577
2013-10-21T00:00:00Z